Coronavirus Live Count Map India
remove_red_eye 521 Views
#Hematology #Oncology #Pathology and Lab Medicine #Pharmacist #Radiology
The FDA has approved tucatinib for treating advanced, HER2-positive breast cancer patients who have received at least one prior therapy.
The highly selective HER2-directed tyrosine kinase inhibitor, approved in combination with trastuzumab plus capecitabine, is indicated for patients with metastatic breast cancer or advanced but unresectable disease. Data from the HER2CLIMB study, which randomized 612 previously treated breast cancer patients 2:1 to trastuzumab and capecitabine plus either tucatinib or placebo, support the approval… (Medpage Today)